Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
The company is headquartered in Hampton, New Jersey.
| Country | United States |
| IPO Date | Mar 10, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 186 |
| CEO | Anthony Marucci |
Contact Details
Address: Perryville III Building, Suite 220 Hampton, New Jersey 08827 United States | |
| Phone | 908 200 7500 |
| Website | celldex.com |
Stock Details
| Ticker Symbol | CLDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000744218 |
| CUSIP Number | 15117B202 |
| ISIN Number | US15117B2025 |
| Employer ID | 13-3191702 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anthony S. Marucci M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer and Executive Vice President |
| Sam Martin CPA | Senior Vice President, Chief Financial Officer, Secretary and Treasurer |
| Elizabeth Crowley | Chief Product Development Officer and Senior Vice President |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sarah Cavanaugh | Senior Vice President of Corporate Affairs and Administration |
| Freddy A. Jimenez Esq. | Senior Vice President and General Counsel |
| Dr. Ronald A. Pepin Ph.D. | Chief Business Officer and Senior Vice President |
| Dr. Richard M. Wright Ph.D. | Chief Commercial Officer and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2025 | SCHEDULE 13G | Filing |
| Jun 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 6, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |